Literature DB >> 26821633

Implantable Cardioverter-Defibrillators at End of Battery Life: Opportunities for Risk (Re)-Stratification in ICD Recipients.

Faisal M Merchant1, Tammie Quest2, Angel R Leon3, Mikhael F El-Chami3.   

Abstract

Although implantable cardioverter-defibrillators (ICDs) are frequently viewed as a lifelong commitment in that patients are routinely scheduled for generator exchange (GE) at end of battery life, several considerations should prompt a reevaluation of risks and benefits before GE. Compared with initial ICD implant, patients receiving replacement devices are older, and have more comorbidities and shorter life expectancy, all of which may limit the benefit of ICD therapy following GE. Additionally, GE is associated with significant complications, including infection, which may increase the risk of mortality. In this paper, we review recent data regarding opportunities for risk stratification before GE, with a particular focus on those with improved left ventricular function and those who have not experienced ICD therapies during the first battery life. We also provide a broader perspective on ICD therapy, focusing on how decisions regarding GE may affect goals of care at the end of life.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac arrhythmias; generator exchange; heart failure; risk assessment; sudden cardiac death; ventricular function

Mesh:

Year:  2016        PMID: 26821633     DOI: 10.1016/j.jacc.2015.11.033

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

Review 1.  Arrhythmic risk stratification in heart failure: Time for the next step?

Authors:  Konstantinos A Gatzoulis; Antonios Sideris; Emmanuel Kanoupakis; Skevos Sideris; Nikolaos Nikolaou; Christos-Konstantinos Antoniou; Theofilos M Kolettis
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-02-03       Impact factor: 1.468

Review 2.  When Is It Safe Not to Reimplant an Implantable Cardioverter Defibrillator at the Time of Battery Depletion?

Authors:  Sana M Al-Khatib; Daniel J Friedman; Gillian D Sanders
Journal:  Card Electrophysiol Clin       Date:  2018-03

3.  Ultrasound-Induced Wireless Energy Harvesting: From Materials Strategies to Functional Applications.

Authors:  Laiming Jiang; Yang Yang; Yong Chen; Qifa Zhou
Journal:  Nano Energy       Date:  2020-07-22       Impact factor: 17.881

4.  The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients.

Authors:  Daniel J Friedman; Marat Fudim; Robert Overton; Linda K Shaw; Divyang Patel; Sean D Pokorney; Eric J Velazquez; Sana M Al-Khatib
Journal:  Am Heart J       Date:  2018-04-04       Impact factor: 4.749

Review 5.  Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Systematic Review and Meta-Analysis of Randomized Trials and Propensity Score-Matched Studies.

Authors:  Khi Yung Fong; Colin Jun Rong Ng; Yue Wang; Colin Yeo; Vern Hsen Tan
Journal:  J Am Heart Assoc       Date:  2022-06-03       Impact factor: 6.106

6.  Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial.

Authors:  Selcuk Adabag; Kristen K Patton; Alfred E Buxton; Thomas S Rector; Kristine E Ensrud; Kairav Vakil; Wayne C Levy; Jeanne E Poole
Journal:  JAMA Cardiol       Date:  2017-07-01       Impact factor: 14.676

Review 7.  The subcutaneous implantable cardioverter defibrillator--review of the recent data.

Authors:  Stacy B Westerman; Mikhael El-Chami
Journal:  J Geriatr Cardiol       Date:  2018-03       Impact factor: 3.327

Review 8.  Time to Shock the System: Moving Beyond the Current Paradigm for Primary Prevention Implantable Cardioverter-Defibrillator Use.

Authors:  Faisal M Merchant; Wayne C Levy; Daniel B Kramer
Journal:  J Am Heart Assoc       Date:  2020-02-24       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.